Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589180 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL54645 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL10597663 | 0.77 | CYP1A2 (0.46) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL5700690 | 0.71 | CYP1A2 (0.41) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL1947835 | 0.70 | AHR (0.41) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL10898650 | 0.68 | CYP1A2 (0.45) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL9548219 | 0.67 | AHR (0.38) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL7785366 | 0.66 | CYP1A2 (0.42) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL8196063 | 0.66 | CYP1A2 (0.42) | CYP1A2CYP2D6TRPA1HRH4 | |
| SCHEMBL10489065 | 0.66 | AHR (0.36) | CYP1A2CYP2D6TRPA1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200091437-A1 | 9,10-DIHYDRO-ACRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | CELL THERAPEUTICS,INC. | 2003-11-20 | — | — | US | claimed |
| US-6638938-B1 | By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic | CELL THERAPEUTICS, INC. | 2003-10-28 | — | — | US | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-5824677-A | SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE | CELL THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | claimed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| US-11158814-B2 | 9,10-dihydro-acridine derivative, and preparation method and use thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200091437-A1 | 9,10-DIHYDRO-ACRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-1960411-B1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9163046-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-8546595-B2 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120202956-A1 | Halogen Substituted Heteroatom-Containing Metallocene Compounds for Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-08-09 | — | — | US | disclosed |
| US-8173828-B2 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110288249-A1 | Halogen Substituted Heteroatom-Containing Metallocene Compounds for Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-11-24 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7868197-B2 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100113717-A1 | Process For Producing Substituted Metallocene Compounds For Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2010-05-06 | — | — | US | disclosed |
| US-7709670-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1866322-B1 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7667064-B2 | high weight average molecular weight while having a relatively narrow molecular weight distribution, resulting in high strength polyolefin; e.g. dimethylsilandiyl(eta 5-2-methyl-4-bromoinden-1-yl)(N-tert-butylamido)titanium dichloride | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009099582-A2 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7557171-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7538168-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1971617-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1960411-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1960442-A1 | HALOGEN SUBSTITUTED HETEROATOM-CONTAINING METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2008011518-A2 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007146786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1866322-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7307177-B2 | Metallocene complexes, their synthesis and use in catalyst systems for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1841448-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | Diakine Therapeutics, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1833859-A2 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7253182-B2 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | SOFOTEC GMBH & CO. KG (DE) | 2007-08-07 | — | — | US | disclosed |
| US-7247630-B2 | Uses of tricyclic compounds | CELL THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2007070046-A1 | HALOGEN SUBSTITUTED HETEROATOM-CONTAINING METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070040-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070038-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135623-A1 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135594-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135593-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1735354-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | Exxonmobil Chemical Company Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1690864-A2 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS, INC. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060160736-A1 | Pharmaceutical compositions and methods for restoring beta-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160967-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-07-20 | — | — | US | disclosed |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060135353-A1 | Metallocene complexes, their synthesis and use in catalyst systems for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006065468-A1 | METALLOCENE COMPLEXES, THEIR SYNTHESIS AND USE IN CATALYST SYSTEMS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065844-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065843-A2 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005105864-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-6855713-B2 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | CELL THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| EP-1165534-B1 | BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-6825180-B2 | CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS | CELL THERAPEUTICS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-6774130-B2 | TREATING CHRONIC INFLAMMATORY DISEASE, CHRONIC INTESTINAL INFLAMMATION, ARTHRITIS, PSORIASIS, ASTHMA AND AUTOIMMUNE DISORDERS; TH1 CELL-MEDIATED DISORDERS; FOR EXAMPLE, 1,2,3,6-TETRAHYDRO-7H-PURINE-2,6-DIONE DERIVATIVES | CELL THERAPEUTICS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1369414-A1 | Enantiomerically pure Arylcycloalkyl hydroxycarboxylic esters, processes for their preparation and their use as modulators of muscarinic receptors | Noe, Christian R. (AT) | 2003-12-10 | — | — | EP | disclosed |
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | Noe, Christian | 2003-11-27 | — | — | US | disclosed |
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | CELL THERAPEUTICS,INC. | 2003-11-20 | — | — | US | disclosed |
| US-6638938-B1 | By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic | CELL THERAPEUTICS, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1347976-A2 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBIOTRS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS, INC. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6613795-B2 | Respiratory system disorders; muscle relaxants | Noe, Christian (DE) | 2003-09-02 | — | — | US | disclosed |
| US-20030162801-A1 | Tricyclic compounds and their uses | GONG BAOQING (US) | 2003-08-28 | — | — | US | disclosed |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-6586429-B2 | For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders | CELL THERAPEUTICS, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-0937041-B1 | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament | NOE CHRISTIAN R (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003024451-A1 | 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002094824-A1 | PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CHRISTIAN NOE AND ERNST MUTSCHLER | 2002-11-21 | — | — | US | disclosed |
| WO-2002068421-A2 | TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING | CELL THERAPEUTICS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002062785-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1165534-A2 | BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2002-01-02 | — | — | EP | disclosed |
| US-6323207-B1 | TREATMENT OR REDUCTION OF TISSUE DAMAGE DUE TO ISCHAEMIA WHICH COMPRISES ADMINISTERING TO A HOST SUFFERING FROM ISCHAEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-27 | — | — | US | disclosed |
| US-6307060-B1 | ANTISPASMODIC AGENTS | Noe, Christian | 2001-10-23 | — | — | US | disclosed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6127423-A | USED IN DISEASES IN WHICH THE LTB4-RECEPTOR-ANTAGONISTIC PROPERTIES PLAY A PART, INCLUDING ARTHRITIS, ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES, E.G., CHRONIC BRONCHITIS, PSORIASIS, ULCERATIVE COLITIS, GASTRO- OR ENTEROPATHY | BOEHRINGER INGELHEIM KG (DE) | 2000-10-03 | — | — | US | disclosed |
| US-6114335-A | Benzoylguanidine derivatives, process for their preparation their use in the preparation of medicines | BOEHRINGER INGELHEIM KG (DE) | 2000-09-05 | — | — | US | disclosed |
| WO-2000017176-A2 | BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-30 | — | — | WO | disclosed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0937041-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | Noe, Christian R. (DE) | 1999-08-25 | — | — | EP | disclosed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0882031-A1 | NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES | Boehringer Ingelheim Pharma KG (DE) | 1998-12-09 | — | — | EP | disclosed |
| US-5824677-A | SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE | CELL THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5777117-A | ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES | CELL THERAPEUTICS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998021183-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | NOE CHRISTIAN R (AT) | 1998-05-22 | — | — | WO | disclosed |
| US-5750575-A | ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS; CYTOTOXIC AGENTS; MICROBIOCIDES; FUNGICIDES | CELL THERAPEUTICS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5670507-A | Method for reversing multiple drug resistant phenotype | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1997026253-A1 | NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1997-07-24 | — | — | WO | disclosed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135623-A1 | Halogen substituted heteroatom-containing metallocene compounds for olefin polymerization | OPRM1, POLM, AP1M1 | CYP1A2 661/4885CYP2D6 1342/4885TRPA1 795/4885 |
| US-11158814-B2 | 9,10-dihydro-acridine derivative, and preparation method and use thereof | GAPVD1, DHX9, DHRS9 | CYP1A2 167/4885CYP2D6 208/4885TRPA1 29/4885 |
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | CYP1A2 3197/4885CYP2D6 2243/4885TRPA1 2690/4885 |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | CYP1A2 4847/4885CYP2D6 4716/4885TRPA1 4251/4885 |
| US-20070135594-A1 | Halogen substituted metallocene compounds for olefin polymerization | MLX, AP1M1, AP2M1 | CYP1A2 2053/4885CYP2D6 2658/4885TRPA1 1586/4885 |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | TPMT, IL2, NFATC1 | CYP1A2 1270/4885CYP2D6 807/4885TRPA1 1631/4885 |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CYP1A2 2390/4885CYP2D6 1324/4885TRPA1 1912/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | CYP1A2 4806/4885CYP2D6 4720/4885TRPA1 4591/4885 |
| US-20030162801-A1 | Tricyclic compounds and their uses | NFATC1, MAVS, STAT3 | CYP1A2 2305/4885CYP2D6 3147/4885TRPA1 1182/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | CYP1A2 2672/4885CYP2D6 2381/4885TRPA1 860/4885 |
| US-20200091437-A1 | 9,10-DIHYDRO-ACRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | GAPVD1, DHX9, DHRS9 | CYP1A2 167/4885CYP2D6 208/4885TRPA1 29/4885 |
| US-20100113717-A1 | Process For Producing Substituted Metallocene Compounds For Olefin Polymerization | OSBP, OSBPL3, OSBP2 | CYP1A2 820/4885CYP2D6 1293/4885TRPA1 547/4885 |
| US-20110288249-A1 | Halogen Substituted Heteroatom-Containing Metallocene Compounds for Olefin Polymerization | OPRM1, POLM, AP1M1 | CYP1A2 661/4885CYP2D6 1342/4885TRPA1 795/4885 |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | CYP1A2 22/4885CYP2D6 54/4885TRPA1 2890/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | CYP1A2 4172/4885CYP2D6 2939/4885TRPA1 1359/4885 |
| US-20070135593-A1 | Halogen substituted metallocene compounds for olefin polymerization | ZKSCAN2, ZRANB2, ZC3H18 | CYP1A2 758/4885CYP2D6 1117/4885TRPA1 146/4885 |
| US-20060160967-A1 | Halogen substituted metallocene compounds for olefin polymerization | OR10J3, ZRANB2, SLC39A3 | CYP1A2 1512/4885CYP2D6 954/4885TRPA1 159/4885 |
| US-20060135353-A1 | Metallocene complexes, their synthesis and use in catalyst systems for olefin polymerization | MCM5, MLX, NR0B2 | CYP1A2 2448/4885CYP2D6 3405/4885TRPA1 2636/4885 |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | CYP1A2 2409/4885CYP2D6 2519/4885TRPA1 438/4885 |
| US-20120202956-A1 | Halogen Substituted Heteroatom-Containing Metallocene Compounds for Olefin Polymerization | OPRM1, POLM, AP1M1 | CYP1A2 661/4885CYP2D6 1342/4885TRPA1 795/4885 |
| US-20060160736-A1 | Pharmaceutical compositions and methods for restoring beta-cell mass and function | IAPP, PNLIP, AMY2A | CYP1A2 4507/4885CYP2D6 4510/4885TRPA1 4594/4885 |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | OSBP, OSBPL3, OSBP2 | CYP1A2 820/4885CYP2D6 1293/4885TRPA1 547/4885 |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | CYP1A2 85/4885CYP2D6 61/4885TRPA1 1868/4885 |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | XDH, MAVS, TPX2 | CYP1A2 1838/4885CYP2D6 3142/4885TRPA1 1832/4885 |
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | CYP1A2 3197/4885CYP2D6 2243/4885TRPA1 2690/4885 |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | CYP1A2 17/4885CYP2D6 12/4885TRPA1 2414/4885 |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | CYP1A2 3217/4885CYP2D6 3181/4885TRPA1 631/4885 |
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | HIF1AN, LPCAT3, PLAAT2 | CYP1A2 4318/4885CYP2D6 4689/4885TRPA1 3124/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | CYP1A2 4507/4885CYP2D6 4510/4885TRPA1 4594/4885 |
| US-20030220400-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | CYP1A2 17/4885CYP2D6 12/4885TRPA1 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.